Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ACP3 | P15309 | 1/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CDC42 | P60953 | 1/20 | 0.50 |
| ▸ | RAC1 | P63000 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844006 | 1.00 | CYP1A2 (0.56) | CYP1A2ALDH1A1ACP3LDHAL3MBTL1 | |
| SCHEMBL8933321 | 0.84 | ALDH1A1 (0.47) | CYP1A2ALDH1A1ACP3L3MBTL1CES2 | |
| SCHEMBL7017619 | 0.84 | ALDH1A1 (0.57) | CYP1A2ALDH1A1ACP3L3MBTL1PTGS2 | |
| SCHEMBL11778400 | 0.84 | AKR1C3 (0.69) | CYP1A2L3MBTL1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL378101 | 0.82 | KMT2A (0.49) | CYP1A2ALDH1A1CES2CES1NPC1 | |
| SCHEMBL7473317 | 0.82 | PARP10 (0.52) | CYP1A2ALDH1A1ACP3CES2CES1 | |
| SCHEMBL11451243 | 0.81 | MAPT (0.56) | ALDH1A1CES2CES1MAPTTSHR | |
| SCHEMBL3089210 | 0.81 | ALDH1A1 (0.62) | CYP1A2ALDH1A1CES2CES1NPC1 | |
| SCHEMBL6201289 | 0.80 | ALDH1A1 (0.61) | CYP1A2ALDH1A1ACP3L3MBTL1CES2 | |
| SCHEMBL11302672 | 0.80 | SRD5A2 (0.56) | PTGS1CES2CES1TSHRPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| CN-116675642-A | Preparation method of chiral aporphine alkaloid | 智简生物科技(上海)有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-3571205-B1 | THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023155873-A1 | CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF IN PHARMACEUTICS | 江苏恒瑞医药股份有限公司 | 2023-08-24 | — | — | WO | disclosed |
| CN-114524798-B | Benzodithiocarbazaheterocycle derivative and preparation method and application thereof | 华南师范大学 | 2023-04-07 | — | — | CN | disclosed |
| US-20220331316-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| CN-114524798-A | Benzodithiocarbazaheterocycle derivative and preparation method and application thereof | 华南师范大学 | 2022-05-24 | — | — | CN | disclosed |
| EP-3901159-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-106999479-B | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | 米伦纽姆医药公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3517112-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20060189606-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6358971-B1 | FOR INHIBITING THE GROWTH OF A PICORNAVIRUS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| CN-1292697-A | Anti-viral compound | LILLY CO ELI (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5374656-A | Nervous system disorders, gastrointestinal disorders | RHONE-POULENC RORER, S.A. (FR) | 1994-12-20 | — | — | US | disclosed |
| EP-0045165-B1 | RHODANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITORS CONTAINING SUCH DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1986-03-12 | — | — | EP | disclosed |
| US-4446143-A | Rhodanine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-05-01 | — | — | US | disclosed |
| EP-0045165-A1 | Rhodanine derivatives, a process for their preparation, and aldose reductase inhibitors containing such derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | CYP1A2 356/4885ALDH1A1 1512/4885ACP3 2781/4885 |
| US-20220331316-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | CYP1A2 356/4885ALDH1A1 1512/4885ACP3 2781/4885 |
| US-20060189606-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | CYP1A2 3179/4885ALDH1A1 1497/4885ACP3 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.